Zugriffszahlen seit März 2016. Zugriffszahlen aus dem Vorgängersystem werden nicht mitberücksichtigt.

Total Visits

Views
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia83

Total Visits Per Month

April 2021May 2021June 2021July 2021August 2021September 2021October 2021
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia0427320

Top country views

Views

Top cities views

Views